Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.
Rosalie A ScholtesCharlotte M MosterdAnne C HespMark M SmitsHiddo J Lambers HeerspinkDaniël H van RaaltePublished in: Diabetes, obesity & metabolism (2022)
In people with T2D, SGLT2 inhibition in combination with an ARB had a larger blood pressure-lowering effect versus placebo than either of the drugs alone. Our data further suggest that the mechanisms underlying these blood pressure reductions at least partially differ between these agents.